



Review Article

Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment

Bent-Are Hansen¹, Øystein Wendelbo^{2,3}, Øyvind Bruserud⁴, Anette Lodvir Hemsing⁵, Knut Anders Mosevoll⁵ and Håkon Reikvam^{5,6}.

¹ Department of Medicine, Haralds plass Deaconess Hospital, Bergen, Norway.

² VID Specialized University, Faculty of Health, Bergen, Norway.

³ Department of Cardiology, Haukeland University Hospital, Bergen, Norway.

⁴ Department of Anesthesiology and Intensive care, Haukeland University Hospital, Bergen, Norway.

⁵ Department of Medicine, Haukeland University Hospital, Bergen, Norway.

⁶ Department of Clinical Science, University of Bergen, Bergen, Norway.

Competing interests: The authors declare no conflict of Interest.

Abstract. Acute leukemias are a group of aggressive malignant diseases associated with a high degree of morbidity and mortality. An important cause of both the latter is infectious complications. Patients with acute leukemia are highly susceptible to infectious diseases due to factors related to the disease itself, factors attributed to treatment, and specific individual risk factors in each patient. Patients with chemotherapy-induced neutropenia are at particularly high risk, and microbiological agents include viral, bacterial, and fungal agents. The etiology is often unknown in infectious complications, although adequate patient evaluation and sampling have diagnostic, prognostic and treatment-related consequences. Bacterial infections include a wide range of potential microbes, both Gram-negative and Gram-positive species, while fungal infections include both mold and yeast. A recurring problem is increasing resistance to antimicrobial agents, and in particular, this applies to extended-spectrum beta-lactamase resistance (ESBL), *Pseudomonas aeruginosa*, methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE) and even carbapenemase-producing *Enterobacteriaceae* (CPE). International guidelines for the treatment of sepsis in leukemia patients include the use of broad-spectrum Pseudomonas-acting antibiotics. However, one should implant the knowledge of local microbiological epidemiology and resistance conditions in treatment decisions. In this review, we discuss infectious diseases in acute leukemia with a major focus on febrile neutropenia and sepsis, and we problematize the diagnostic, prognostic, and therapeutic aspects of infectious complications in this patient group. Meticulously and thorough clinical and radiological examination combined with adequate microbiology samples are cornerstones of the examination. Diagnostic and prognostic evaluation includes patient review according to the multinational association for supportive care in cancer (MASCC) and sequential organ failure assessment (SOFA) scoring system. Antimicrobial treatments for important etiological agents are presented. The main challenge for reducing the spread of resistant microbes is to avoid unnecessary antibiotic treatment, but without giving to narrow treatment to the febrile neutropenic patient that reduce the prognosis.

Keywords: Leukemia; Chemotherapy; Stem cell transplantation; Infectious disease; Sepsis; Bacteremia.

Citation: B.A. Hansen, Ø. Wendelbo, Bruserud Ø., Hemsing A.L., Mosevoll K.A., Reikvam H. Febrile netutropenia in acute leukemia; epidemiology, etiology, pathophysiology and treatment. *Mediterr J Hematol Infect Dis* 2020, 12(1): e2020009, DOI: <http://dx.doi.org/10.4084/MJHID.2020.009>

Published: January 1, 2020

Received: September 30, 2019

Accepted: December 17, 2019

Correspondence to: MD PhD Håkon Reikvam, Department of Clinical Science, University of Bergen, Bergen, Norway. N-5021 Bergen, Norway. Tel. 55 97 50 00; Fax. 55 97 29 50. E-mail: Hakon.Reikvam@med.uib.no

Introduction. Acute leukemia is a group of highly malignant blood disorders characterized by clonal growth of immature progenitor cells in the bone marrow. This infiltration leads to severe thrombocytopenia, anemia and leukopenia, and that makes fatal within a few weeks this disease if left untreated. There are three major groups of acute leukemias; acute myeloid leukemia (AML),¹ acute lymphocytic leukemia (ALL),² and on very rare occasions mixed phenotype acute leukemia (MPAL).³ The clinical presentation is often similar, although the treatment protocols are different, and the diseases can only be cured by intensive chemotherapy treatment, possibly in combination with allogeneic hematopoietic stem cell transplantation (allo-HSCT).¹⁻³ Infectious complications continue to be a significant cause of both morbidity and mortality in acute leukemia patients. In the present article we review the current and update knowledge regarding pathophysiology, epidemiology and etiology of infectious complication in patients with acute leukemia. Finally, we discuss optimal approaches to adequate diagnosis and discuss treatment options for this demanding patient group.

Pathophysiology and Risk Factors. The clinical susceptibility for infections among patients with hematological malignancies is multifactorial. The risk of development and the severity of infections are determinate by a complex interplay between the pathogen and its virulence, and the degree of impaired defense mechanisms of the host. The risk of infection can broadly be divided into (i) disease-associated

factors, (ii) patient-related factors, and (iii) treatment-related factors (**Figure 1**).

Disease-associated Factors. In acute leukemia, normal bone marrow function is to more or less extent, replaced by abnormal maturation and dysregulated proliferative immature cells, resulting in neutropenia and impaired granulocyte function.¹⁻³ It is well established that quantitative reduction in circulating immune cells makes the organisms more susceptibility for invasive infections.⁴ Furthermore, immature myeloid cells have the potential to inhibit the antigen-specific T-cell response.⁵ The humoral immune system is also affected by the disease and its treatment, so the majority of patients will have immunoglobulins' deficiency. IgG and IgM being the most affected immunoglobulins, and humoral defect immunity can also be present in patients achieving complete remission.⁶ Finally, the incidence and severity of infections and sepsis are very different in AML patients compared to ALL patients. Induction treatment induces in AML more prolonged neutropenia, which favors infectious complications with early deaths, significantly more frequent in AML patients compared to ALL patients.⁷⁻¹⁰

Patient-related Factors. Intrinsic properties related to the patient itself are also important in the assessment of infection risk in patients with acute leukemia. Age itself is a major risk for developing infectious complications during the treatment of acute leukemia.¹¹ The natural function of the immune system declines by




Figure 1. Risk factors for infections in patients with leukemia. The figure summarizes risk factors for infection in leukemia patients, which broadly could be divided into disease specific factors, patient related factors, and treatment related factors.

age,¹² as both the B- and T-cell function will be reduced with increasing age.¹² In addition, elderly patients are often frailer and have comorbidities affecting infection susceptibility,¹¹ increasing the risk of both morbidity and mortality of the disease and the treatment. Although studies have found that older patients are not more susceptible to infections,¹³ one must take into account that older patients are often treated with milder and less toxic chemotherapy regimens affecting infectious risk.¹¹ Age and comorbidity burden increase the risk for intensive care unit (ICU) admission,¹⁴ and severe comorbidity is a strong predictor for early death in acute leukemia patients, death often caused by infectious complications.¹⁵

In recent years, there has also been an increased focus on nutrition, and undernourishment is considered a critical risk for serious infection complications.¹⁶ Nutritional problems are often linked to the treatment of leukemia, as nausea, vomiting, and emesis are common treatment side effects. Consequently, reduced food intake and weight loss are often complementarities to the treatment, and reduced nutritional intake increases the risk of serious infections. Low initial body mass index (BMI) and more pronounced weight loss during treatment courses are strong prognostic indicators associated with lower survival and both bacterial and fungal infections.¹⁷

Furthermore, global challenges regarding the diagnostic and treatment of infectious complications in acute leukemia patients are also important to take into considerations. For example, for children treated for ALL, the rates of infection-associated mortality are up to 10-times higher in low- and middle-income countries than in high-income countries.¹⁸ This is due to several underlying factors such as shortage of trained personnel, supplies, diagnostic tools, and adequate infrastructures as well as undernourishment and risk of multiple drug-resistant organisms (MDROs).¹⁸ Also, in high-income countries, socioeconomic status seems to be a risk factor for infection and early complications in acute leukemia patients.¹⁹ Finally, lower early mortality is also registered in centers with larger patients' volume and more special cancer centers. It may result from differences in the hospital or provider experience and supportive care.^{20,21}

Treatment-related Factors. Treatment of acute leukemia requires intensive chemotherapy with high dose drugs, often in a combination regimen, resulting in prolonged neutropenia, often lasting for weeks.¹⁻³ The risk of developing more serious and complicated infections is clearly linked to the degree and duration of neutropenia.⁴ The risk of severe infections is not uniform among these patients, and factors associated with increased susceptibility for infectious

complications include prolonged neutropenia,²² use of salvage chemotherapy,²³ and relapsed disease.²⁴ However, other factors than the leukopenia itself are associated with infectious risk.

Mucosal barriers separate self from non-self and are the first line of defense against external pathogens. Epithelia at mucosal surfaces must allow selective paracellular flux, and at the same time preventing the passage of potentially infectious agents.²⁵ Leukemia patients receiving cytotoxic therapy or radiotherapy will experience mucosal barrier injury, often termed mucositis. The barrier disruption will create an entrance point for resident microorganisms, with the potential to cause bloodstream infections.²⁶ Consequently, the infections are typical due to those opportunistic pathogens that inhabit the skin, oral cavity, and the gastrointestinal tract, rather than more conventional pathogens such as *Streptococcus pneumoniae* (*S. pneumoniae*) and *Staphylococcus aureus* (*S. aureus*).²⁷

Furthermore, gastrointestinal bacterial colonization will often be affected during the treatment course of acute leukemia, both through mucosal barrier injuries, and the use of broad spectra antibiotics and other microbial agents.^{26,28} This will affect the natural bacterial flora of the intestinal tract, often termed the microbiota. Decreases in both oral and feces microbial diversity are associated with the receipt of carbapenem antibiotics.²⁹ Furthermore, loss of microbial diversity throughout treatment is associated with the risk of infection²⁹ and with a higher risk of mortality in the setting of allo-HSCT.³⁰ *Clostridium difficile* is clearly associated with the use of broad spectra antibiotics, and the risk of clinical infections is increased among leukemia patients and associated with increased mortality.³¹ In addition, the use of antibiotics sets the patients for risk for colonization with MDROs.³² Colonization with MDROs, especially *Enterococcus faecalis* (*E. faecalis*), *Enterococcus faecium* (*E. faecium*), and *Stenotrophomonas maltophilia* (*S. maltophilia*), has been clearly associated with risk of infections and non-relapse-related mortality in the setting of allo-HSCT in AML patients.^{33,34} Colonization in the intestine, previous use of antimicrobial therapy, especially beta-lactams and cephalosporins, and total length of hospitalization, all increases the risk of more for MDROs, including extended-spectrum beta-lactamase resistance (ESBL).^{32,35-38} Central venous catheters (CVCs) are an essential tool for an appropriate management of patients with acute leukemia. However, CVCs are an entrance port for bacteria into the bloodstream and a potential for bacterial colonization. CVCs increase the risk for bloodstream infections, and the infection risk is correlated with the numbers of CVC manipulations. The patients are especially vulnerable to gram-positive infections.³⁹ The rate of central-line associated

bloodstream infections is estimated to 2/1000 catheter days,⁴⁰ and delaying CVC placement in acute leukemia does not affect the reduction of infectious risk.⁴¹ In contrast, antiseptic coating of intravascular catheters may be effective in decreasing catheter-related colonization and subsequent infections.⁴² Early removal of CVCs should always be considered for leukemia patients with undocumented sepsis.⁴³ Furthermore, in recent years the use of peripherally inserted central catheters is increasing and is associated with a lower risk of bloodstream infections.⁴⁴ A study from China in the period 2011-2014 demonstrated that the risk of BSI in the use of peripherally inserted central catheters in cancer patients was 0.05/1000 catheter days, and the overall risk of infections was approximately 1/1000 catheter days.⁴⁴

Taken together, all factors related to one of these three conditions increase the risk of infections in leukemia patients, and proper evaluation of all these risk factors should be considered when evaluating leukemia patients for prophylaxis and treatment of infectious complications.

Ferbril Netropenia and Sepsis. According to the third international consensus definitions for sepsis and septic shock, sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.⁴⁵ Organ dysfunction is identified as an acute change in the sequential organ failure assessment (SOFA) score.⁴⁶ Septic shock is defined as a subset within sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to increase the mortality risk substantially. Bacteremia is defined as the growth of bacteria in blood cultures, although infections do not have to be proven to diagnose sepsis at the onset. These criteria also define sepsis in patients with acute leukemia. These patients are especially prone to bacterial infections following chemotherapy due to severe neutropenia,^{47,48} and their cellular immune defect represents an additional predisposition to infections to fungi, parasites, and viruses. However, leukemic patients are at risk for infectious diseases and can present altered symptoms and signs due to an impaired inflammatory response. Thus a high index of suspicion is warranted.

Clinical Presentation and Diagnosis. Leukemic patients may present altered symptoms and signs for sepsis and infections because of an impaired inflammatory response, thus discovering an infection, and the likely focus might represent a major challenge. However, sepsis should be suspected in patients presenting typical signs and symptoms for infections⁴⁹ including fever (core temperature $>38^{\circ}\text{C}$), hypothermia ($<36^{\circ}\text{C}$), heart rate >90 beats per minute, tachypnea (>30 breaths per minute), altered mental status, significant edema or positive fluid balance (>20 ml/kg

over 24 hours), or hyperglycemia (plasma glucose >110 mg/dl or 7.7 mmol/l) in the absence of diabetes. Besides, one should be aware of organ-specific symptoms associated with infectious diseases such as respiratory symptoms (cough, rhinorrhea, and respiratory distress), gastrointestinal symptoms (nausea, vomiting, diarrhea, and abdominal pain), and consciousness disturbance which all should lead to further diagnostic work-up. Notably, mucositis and cutaneous signs such as rash, local heat, swelling, exudate, fluctuation, or ulceration can manifest infectious diseases in the leukemic patient.

These latter signs will determine the likely source of infection and the status of the organ function. The Multinational Association for Supportive Care in Cancer (MASCC)-score, Talcott's classification and the clinical index of stable febrile neutropenia (CISNE) tool could help the assessment of the patients' risk for developing a serious infection in patients with febrile neutropenia.⁵⁰ MASCC-score index of <21 indicates a low risk, and the patient could be considered for outpatient treatment with oral antibiotics. With high risk (MASCC >21) or clinical suspicion of sepsis, the patient should always be admitted to the hospital.⁵⁰ However, it is important to be aware that only a minority of the patients (28%) in the original MASCC-cohort were patients with acute leukemia.⁵¹ Direct comparison between CISNE and MASCC-score demonstrates that CISNE gives a more specific identification of low-risk patients, although with lower certainty in patients with acute leukemia.⁵² The 2016 3.0 sepsis definition recommended qSOFA as a screening tool for patients with suspected sepsis. qSOFA has so far shown inferior sensitivity compared to MASCC-score for risk assessment for sepsis development in neutropenic patients.^{53,54} Cautious use of scoring systems, and still be clinical vigilant is important, as more validation of these scoring systems are needed, also in leukemia-cohorts.

Hemodynamic parameters can indicate organ dysfunctions and sepsis development; arterial hypotension (systolic blood pressure <90 mmHg, mean arterial pressure <70 mmHg, or a systolic blood pressure decrease of >40 mmHg in adults or <2 standard deviations (SD) below normal for age), mixed venous oxygen saturation $>70\%$, cardiac index >3.5 l/min/m², arterial hypoxemia ($\text{PaO}_2/\text{FiO}_2 < 300$), and acute oliguria (urine output <0.5 ml/kg/h or 45 ml for at least 2 h).

Laboratory testing helps estimate the severity of the infection and may indicate the source of infection.⁴⁹ Inflammatory markers indicating sepsis are leukocytosis (white cell counts (WBC) $>12 \times 10^9/\text{l}$), leukopenia (WBC $<4 \times 10^9/\text{l}$), normal white cell counts with $>10\%$ of immature forms, and plasma C-reactive protein (CRP) or procalcitonin >2 SD above the normal value/range. Organ dysfunction can also easily be

verified in laboratory testing including creatinine increase ≥ 0.5 mg/dl, coagulation abnormalities (international normalized ratio (INR) >1.5 or activated partial thromboplastin time (APTT) >60 seconds), thrombocytopenia (platelet count $<100\,000/\mu\text{l}$), and hyperbilirubinemia (plasma total bilirubin >4 mg/dl or $70\ \mu\text{mol/l}$). Hyperlactataemia (>3 mmol/l) can indicate decreased tissue perfusion.

Appropriate cultures and Gram-stains (blood, sputum, urine, fluids, and cerebrospinal fluid) are helpful to identify the source of the infection and reveal the microbe. Blood cultures should ideally be taken during fever and before the onset of antibiotics, and are found positive in 40-60% of patients with septic shock. Positive microbial findings can be crucial for the correct treatment of the patient. The chest radiograph will aid in the diagnosis of pneumonia, empyema, and acute lung injury. Abdominal ultrasound or computer tomography (CT) scanning is indicated if abdominal sepsis is suspected, and magnet resonance imaging (MRI) can help find infections in soft tissues. Several factors can affect the outcome of FN, including the patient's underlying disease, age, patients' clinical condition, number of infectious foci, duration of the neutropenia, the onset of antimicrobial therapy, geographical location, and local profile of antimicrobial resistance.⁵⁵

Despite advances in antimicrobial treatment, bloodstream infections (BSIs) prolong hospital stay,

increase direct patient care costs, and cause considerable mortality.^{56,57} In neutropenic patients with fever of unknown origin, the attack rate for BSI is 11%–38%.⁵⁸ Previous studies showed that infections were the cause of death for 50%-80% of acute leukemia patients, and for 50% of patients with lymphoma and solid tumors.⁵⁹ In **Figure 2**, we present an algorithm for the management of FN in leukemia patients, including prognostic, diagnostic, and treatment decision work up.

Bacterial Etiology. Infectious complications in patients with hematological malignancies occur most frequently in patients with chemotherapy-induced cytopenia following intensive chemotherapy,^{60,61} and FN is most common in AML patients. The etiology is often unknown at the onset of infection.⁶² Knowledge of the prevalence of causative bacteria in neutropenic patients with fever is important as infections can rapidly progress, and FN patients can become hemodynamically unstable, as prompt and rapid onset of adequate antimicrobial treatment within one hour is recommended.^{63,64} There are considerable site- and region-specific differences in the incidence of resistant organisms such as methicillin-resistant *S. aureus* (MRSA) and vancomycin-resistant enterococcus (VRE). These local differences may impact the initial choice of empiric antibiotic therapy. Therefore, knowledge of the general and local epidemiology and




Figure 2. Risk factors for infections in patients with leukemia. The figure illustrate an algorithm for management of FN in leukemia patients, including prognostic, diagnostic and treatment decision work up. Abbreviations: ANC, absolute neutrophil count; C, Celcius; FiO₂, Fraction of inspired Oxygen; GCS, Glasgow coma scale; L, liter; MAP, Mean Arterial Pressure; MASCC, Multinational Association for Supportive Care in Cancer; PaO₂, Partial pressure of Oxygen; Pip/tazo, piperacillin/tazobactam; qSOFA, quick Sepsis Related Organ Failure Assessment; SOFA, Sequential Organ Failure Assessment.

Table 1 Most common bacteria causing infection in acute leukemia patients. The most frequent Gram-positives and Gram-negatives causing infections in acute leukemia patients are summarized in the Table. The table presents the most important microbes, their main source for entrance and the possible antimicrobial drugs of choice.

	Microbes	Source	References
Gram-positive microbes	<i>S. aureus</i> -MSSA -MRSA	CVC, skin	[67, 68]
	CoNS	CVC, skin	[69]
	<i>E. faecalis</i> <i>E. faecium</i>	GI-tractus, CVC	[70]
	<i>C. difficile</i>	Lower GI-tractus	[71]
	Viridans group streptococcus	Oral/GI-tractus	[72-75]
	<i>S. pneumoniae</i>	Nasal cavity	[72-75]
Gram-negative microbes	<i>E.coli</i>	GI-tractus, urogenital	[70, 76-81]
	Klebsiella spp.	GI-tractus, urogenital	[70, 76-81]
	<i>A. baumannii</i>	Skin, catheters, environment	[82]
	<i>P. aeruginosa</i>	GI-tractus, environment	[70, 83, 84]

Abbreviations: MRSA: Methicillin-resistant *Staphylococcus aureus*. MSSA: Methicillin-sensitive *Staphylococcus aureus*. CoNS: Coagulase-negative *Staphylococcus*. VRE: Vancomycin Resistant Enterococci.

resistance profiles is of paramount importance in the optimal treatment of febrile neutropenia.^{65,66} The most frequent bacteria causing infections in acute leukemia patients are summarized in **Table 1**.⁶⁷⁻⁸⁴

Previous studies have documented bloodstream infections in 15–38% of patients with hematological malignancies.^{62,85-87} In Europe and the US, Gram-negative organisms were the most predominant pathogens during the 1970s and the 1980s, followed by a shift toward Gram-positive organisms.⁸⁶ In 2000, 76% of all BSI in the US was associated with Gram-positive microbes, of which coagulase-negative staphylococci (CoNS), viridans streptococci and enterococci were the most frequently isolated pathogen.⁸⁷ Recently, a number of reports show a tendency towards an increase of Gram-positive bacteremia.^{62,85-87} This is usually attributed to the increasing use of indwelling CVCs and the use of fluoroquinolone (FQ) prophylaxis which suppresses the aerobic Gram-negative organisms of the gastrointestinal tract. Mortality is lower in patients with Gram-positive bacteremia than in patients with Gram-negative bacteremia.⁸⁶ Epidemiological studies of BSI rank Gram-negative rods with *Escherichia coli* (*E. coli*) as the most frequently isolated pathogen.⁸⁶ More recently, the increased incidence of MDROs, such as Gram-negative *Enterobacteriaceae*, has been the scope of several papers.^{88,89} Gram-negative bacteria are reported as MDROs if not susceptible to at least three of the following antimicrobial categories: antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides or FQs.⁹⁰ In several European countries, > 10% of invasive infections caused by *E. coli* were due to extended-spectrum beta-lactamases (ESBL).^{66,91} *Pseudomonas aeruginosa* (*P. aeruginosa*) is a Gram-negative pathogen associated

with high mortality, and accounts for approximately 5-10% of BSI in hematological patients.⁹² *P. aeruginosa* is characterized by several resistance mechanisms; (i) intrinsically resistant to antimicrobial agents due to low permeability of its cell wall, (ii) genetic capacity to express a vast repertoire of resistance mechanisms, (iii) become resistant through mutations in regulative resistance genes, and (iv) acquire additional resistance genes from other organisms via plasmids, transposons and bacteriophages.⁹³

Carbapenem resistance is reported as high as 3-51% in different geographical regions of Europe.⁹¹ *Acinetobacter* has emerged as a significant cause of health-care-associated infection in critically ill and immunocompromised patients. Mortality rank between 17-50% and *Acinetobacter baumannii* (*A. baumannii*) is estimated to be responsible for about 2-12% of BSI.⁹¹ Oral mucositis, use of CVC and FQ prophylaxis increase the risk of Gram positive BSI. The most frequent isolated pathogen is *staphylococcus* spp, dominated by CoNS that accounts for about 25%-33% of all BSI.^{94,95} The more virulent, *S. aureus* is responsible for only a smaller proportion of infections, accounting for about 5% of BSI.⁸⁶ The incidence of methicillin resistance is higher in CoNS than in *S. aureus*, the median resistance rate of 80% and 56% respectively, and >60% of European centers reporting more than 50% methicilline-resistance in CoNS.^{91,92}

Enterococcus spp. is now the third most frequent group of pathogens in BSI and affects 10-12% of transplant patients. Many centers report a shift from *E. faecalis* to *E. faecium*, the latter being frequently resistant to ampicillin and demonstrate increasing resistance to vancomycin (10.4% in 2014 and 14.9% in 2017).⁹⁶ The mortality rate is high, and in one study from a transplant center in the US, they found a 30-day

mortality of 38%.⁹⁷ Noteworthy, enterococcus spp. in general have low virulence, and BSI with enterococcus spp. have been clearly associated with severe comorbidity, and their direct impact on mortality remains unclear.^{96,98}

The frequency of viridans streptococci in BSI of neutropenic patients with cancer has significantly increased over the last 10–15 years and now accounts for approximately 5%.^{87,99} Risk factors in this patient population include severe neutropenia, oral mucositis, administration of high-dose cytosine arabinoside, and concomitant use of antimicrobial prophylaxis with either trimethoprim-sulfa or an FQ. Viridans streptococci may contribute to acute respiratory distress syndrome; in some studies, mortality rates of 10% have been reported.¹⁰⁰

Treatment of Bacterial Infections. FN is a medical emergency, and early identification followed by diagnostic blood cultures and prompt administration of appropriate intravenous antibiotics remains the cornerstones in the initial management. Harvesting

microbiological cultures and source control obtained by removal or drainage of the infected foci is mandatory. Empiric antibiotic treatment should be started within the first hour after the clinical suspicion is raised, according to guidelines for neutropenic fever and sepsis.⁵⁰ When a causative microbe is diagnosed, a more targeted antibiotic treatment could be possible, resulting in more specific and less broad-spectrum antimicrobial therapy. The main antibiotics and their characteristics are presented in **Table 2**.^{50,67,68,70,71,73-81,101-109}

Adjuvant sepsis-treatment as fluids therapy is important in sepsis treatment, although secondary to antibiotic treatment and adequate source control.¹¹⁰ However, optimization of hemodynamically unstable patients, including volume support supplemented with a vasopressor, inotropic and transfusion of red blood cells (RBCs) in case of persistent hypo-perfusion has the potential to reduce morbidity and mortality and can prolong survival and improve quality of life.^{45,111}

International recommended empiric treatment of

Table 2. Main antibiotics for infection treatment. The table the most relevant antibiotics when treating infections in leukemic patients. The table present the most used drugs, their antimicrobial specter and main advantages and disadvantages in clinical practice.

	Generic	Antimicrobial specter	Drugs	Advantages	Disadvantages	Ref
Beta-lactams	Penicillin	Gram-positives Some anaerobes	Penicillin G	Low toxicity Less resistance driving than cephalosporines	Narrow spectrum	[73-75]
	Aminopenicillin	Gram-positives, also most <i>E. Faecalis</i> Some Gram-negatives	Ampicillin	Less resistance driving than cephalosporines Cover most enterococci	Relative narrow spectrum	[101]
	Penicillinase stable penicillin	Gram-positives	Cloxacilline	Less resistance driving than cephalosporines	Narrow spectrum	[67]
	Cephalosporins, no Pseudomonas or MRSA activity	Covering both Gram-positive and Gram-negative, but not ESBL, <i>P. aeruginosa</i> or MRSA	Cefotaxime Ceftriaxone	Beta-lactam alternative for susceptible microbes	No effect against ESBL-producing microbes	[107-109]
	Cephalosporins Pseudomonas active	Gram-negatives <i>P. aeruginosa</i> Fewer Gram-positives	Ceftazidime Cefepime	Beta-lactams approved as first treatment for neutropenic fever	Ceftazidime give no effect against MSSA	
	Cephalosporins MRSA active	Gram-negatives Gram-positives MRSA	Ceftobiprol Ceftrazoline	Alternative Beta-lactam with MRSA effect	Not approved in neutropenic fever	
	Carbapenems	Gram-negatives also ESBL Gram-positives Anaerobes No MRSA coverage	Meropenem Ertapenem Imipenem	Broad spectrum, also ESBL and anaerobes no effect against enterococci and MRSA Less cross-reactivity for penicillin-allergies'	Resistance driving	[70, 76-81]
	Betelactams with enzyme inhibitors	Gram-negatives also ESBL Gram-positives Anaerobes	Piperacillin-Tazobactam. Ceftazidime-Avibactam. Ceftolozane-Tazobactam. Imipenem-Cilastine.	Pip-Tazo good choice for first line treatment in neutropenic fever Extended broad spectrum, also ESBL and anaerobes	Cross-reactivity for penicillin-allergies	[102]

Non- Beta-lactams	Metronidazole	Anaerobes <i>C. difficile</i>	Metronidazol	Anaerob coverage to primary regime Effect against clostridium	Neuropathies	[71]
	Aminoglycosides	Gram-negatives Gram-positives	Gentamicin Netilmicin Tobramycin	Rapid antimicrobial effect Broad spectrum Little resistance driving	Nephrotoxicity Ototoxicity Small therapeutic window	[103]
	Fluoroquinolons	Gram-negatives	Ciprofloxacin Levofloxacin Moxifloxacin	Good penetration in bone, abscesses	Increasing resistance	[50, 101]
	Glycopeptides	Gram-positives, MRSA, enterococci, CoNS, <i>C. difficile</i>	Vankomycin Teikoplanin Dalbavacin	Often alternative for MRSA; enterococci, CoNS	Nephrotoxicity	[67, 68]
	Oxazolidinones	Gram-positives, MRSA, VRE, CoNS	Linezolid	Good per oral availability	Bone marrow suppression Neuropathies Lactic acidosis	[67, 68]
	Daptomycin	Gram-positives, MRSA, VRE, CoNS	Daptomycin	Well tolerated	Poor oral absorption Poor effect in pneumonia	[67, 68]
	Polymyxines	MDR Gram-negatives including <i>P. aeruginosa</i> , <i>A. baumannii</i> , CRE	Colistin Polymyxin B		Nephrotoxicity Neurotoxicity	[104]
	Fosfomycin	Gram-negatives	Fosfomycin	Alternative as adjuvant in MDR	Resistance development during treatment	[105]
	Trimetoprim/Sulfonamides	Gram-negatives MRSA/MSSA, <i>S. maltophilia</i> <i>P. jirovecii</i> ,	Trimetoprim-sulfa		Nephrotoxicity	[106]

Abbreviations: ESBL: Broad-Spectrum β -Lactamase-Producing Enterobacteriaceae. CPE: Carbapenemase-Producing Enterobacteriaceae. MRSA: Methicillin-resistant *Staphylococcus aureus*. MSSA: Methicillin-sensitive *Staphylococcus aureus*. CoNS: Coagulase-negative *Staphylococcus*. VRE: Vancomycin Resistant Enterococci.

neutropenic fever. International recommended empiric treatment for FN is initial broad covering with pseudomonas acting beta-lactam antibiotic.^{50,81,90,112,113} In cases of septic shock, guidelines recommend two Gram-negative acting antibiotics, usually a beta-lactam and an aminoglycoside. Traditionally a cephalosporin or piperazillin-tazobactam is recommended, although this is challenged by the rapid spread of MDROs making carbapenem treatment necessary.^{70,76,77} This is, however not only the case, as other treatment narrower antibacterial spectra are used in some centers.⁹⁰ The emergence of carbapenemase-producing Enterobacteriaceae (CPE) also makes the carbapenems less secure choice in several parts of the world.⁷⁸⁻⁸¹ Escalation or de-escalation strategies are the two main approaches for treatment, depending on the clinical condition of the patient (**Table 3**).^{50,81,90,112,113} In an escalation strategy, treatment is initiated with less broad coverage, although escalation is performed if the patient responds inadequately to the initial treatment. With de-escalation strategy, broader antimicrobial therapies initiate the treatment, and if the patient's condition improves de-escalation is performed. Both strategies depend on the correction of treatment after appropriate microbiology results. With the rapid

increase of MDROs, all centers treating leukemia patients should carefully follow and monitor for emerging resistant microbes and use the most appropriate treatment, given local epidemiology.

Guidelines used for febrile neutropenia are based on best available data, and a challenge is that studies for febrile neutropenia are usually not specific for leukemia. In **Table 4** we have indicated the main population in the studies supporting the current guidelines. Because patients with solid tumors show different phenotypes and different etiology, direct interpretation from these studies should be careful. We have emphasized the description of the microbiological etiology in the previous section because the suspected pathogenic microbe is decisive when starting treatment. However, both the microbiology and health organization varies in different countries, regions and departments. Monitoring the local microbiology and correction of local guidelines, and always try to choose the lesser resistance driving treatment alternative is important. Recommendations given in the next section reflect this, where the treatment of different resistant microbes are described.

Different local resistance patterns require adaptations

Table 3. Treatment strategies for empiric antibiotic treatment in acute leukemia patients. The table shows the main escalation and de-escalation therapy in acute leukemia patients, the different patient groups suitable for the different strategies and recommended empiric therapy.

	Patient group	Recommended empiric therapy	References
Escalation strategy	All patients, unless criteria for de-escalation approach are present	Anti-pseudomonal cephalosporin (cefepime, ceftazidime) or piperacillin-tazobactam.	[50, 81, 90, 112, 113]
		Other possible options, depending on local epidemiology: Ticarcillin-clavulanate Cefoperazone-sulbactam Piperacillin + gentamicin	
De-escalation strategy	Increased risk for resistant bacteria, such as: • Colonization with a resistant pathogen • Previous infection with a resistant pathogen • Centers in which resistant pathogens are frequently isolated Particularly if presenting in severe clinical conditions	Carbapenem (or a new beta-lactam such as ceftolozane/tazobactam or ceftazidime/avibactam) Combinations, examples • beta-lactam + aminoglycoside • beta-lactam + coverage of resistant Gram-positives • Colistin-based combinations	[50, 81, 90, 112, 113]

Table 4. Treatment options for special problematic microbes. The table shows treatment recommendation for microbes associated with special treatment challenges in patients with acute leukemias. The table is based on European (ECIL) and American (IDSA) recommendations, and references to relevant studies are given in the table. First line treatments are listed first, while second line alternatives are given in parentheses.

Problematic microbes	Recommended antibiotic treatment options	References
Gram-negatives	ESBL	Carbapenems [70, 76, 77, 114] ^{HSCT, C, H, H}
	CPE	Two or more active agent combinations; aminoglycosides, polymyxins, tigecycline, fosfomycin, and meropenem [70, 78-81] ^{HSCT, I, I,}
	<i>P. aeruginosa</i>	Combination therapy, using beta lactam with aminoglycoside or fluoroquinolone [70, 83, 84] ^{HSCT, HSCT, H}
	<i>S. maltophilia</i>	Trimetoprim-sulfa (Combination with either ticarcillin/clavulanate or ceftazidime) [115] ¹
	MDRO <i>A. baumannii</i>	Colistin combination with ampicillin/sulbactam or imipinem or meropenem. Tigecycline combinations. [82] ¹
Gram-positives	CoNS	Glycopeptides; vancomycin and teicoplanin (daptomycin, linezolid, and tigecycline) [69] ^{HSCT}
	MRSA	[68] ¹
	VRE	Linezolid and daptomycin (Quinupristin-dalfopristin, tigecycline, fosfomycin, tedizolid, oritavancin, dalbavancin and telavancin). [70] ^{HSCT}

Abbreviations: ESBL: Broad-Spectrum β-Lactamase-Producing Enterobacteriaceae. CPE: Carbapenemase-Producing Enterobacteriaceae. MRSA. CoNS: Coagulase-negative Staphylococcus. VRE: Vancomycin Resistant Enterococci. Indications of febrile neutropenia publications' main weighting/patient cohort are demonstrated: H; Hematological cohorts, L; Leukemia cohorts, HSCT; Hematological stem cell transplantation, C; Mixed Cancer (both hematological and solid), I; infections, not neutropenia in general

of the empirical treatment. When a specific pathogen is identified, the treatment should be corrected according to resistance as long as the microbiology result is clinically plausible.⁸¹ Before a definitive resistance pattern is given, one will direct treatment after the local resistance patterns for the identified microbe. Relevant antibiotic treatment for unique problematic microbes based on the latest European and American guidelines are presented in **Table 4.**^{68-70,76-84,114,115}

The first choice for treating ESBL is carbapenems, beta-lactams with a time-dependent bactericide

effect.^{70,76,77} Aminoglycosides might also have an effect, although many ESBL-strains harbor resistance to aminoglycosides.⁹² Aminoglycosides have a concentration-dependent bactericide effect depending on peak-concentration and a rapid bactericide effect, in addition, to being synergistic to beta-lactams.¹⁰³

CPE requires a combination of at least two antibiotics.⁷⁸⁻⁸¹ The choices are limited and include high dose prolonged meropenem, aminoglycosides, polymyxins, tigecyclin and fosfomycin, depending on the resistance pattern. High dose of meropenem

increases the risk for side effects; nephrotoxicity of aminoglycosides and polymyxins could be challenging, while resistance development during treatment is a significant disadvantage for tigecyclin and fosfomycin.

P. aeruginosa is often susceptible to pseudomonas active cephalosporines and piperazillin/tazobactam, although it will often develop resistance during treatment.^{70,83,84} Meropenem will also be a suitable choice and double coverage with additional aminoglycoside should be considered, especially in unstable patients and if anti-pseudomas drugs are previously used.¹¹⁶ Tobramycin is the recommended aminoglycoside, as high dose gentamycin no longer is regarded as sufficient even with dosages of 7mg/kg. Gentamycin is now proposed to be removed from The European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for *Pseudomonas* spp.

MDRO *A. baumani* will often be difficult to treat, and represent a major challenge in the treatment of leukemia patients if present.⁸²

CoNS are frequently found in catheter infection and BSI. Although not always very virulent, CoNS might be difficult to treat due to resistance.⁶⁹ Vancomycin is often the first treatment of choice, although treatment has to be corrected after susceptibility-pattern. Cloxacilline, daptomycin, linezolid, and tigecycline are possible alternatives.

The MRSA incidence is varying from region to region, and coverage for MRSA empirically should be considered according to local incidence.⁶⁸ MRSA could be treated with vancomycin and daptomycin, although newer MRSA-active cephalosporins have been developed. Other alternatives are linezolid and tigecycline.

VRE are not very virulent but have a difficult susceptibility-pattern.⁷⁰ Alternative treatments include linezolid and daptomycin. Alternatives are quinupristin–dalfopristin, tigecycline, fosfomycin, tedizolid, oritavancin, dalbavancin and telavancin.

The net antibiotic consumption in society, both for human and animal use is one of the most important predictors for the spread of antibiotic resistance.¹¹⁷ Acute leukemia patients are maybe the most vulnerable of all patients, and among the individuals that easiest acquire resistant microbes due to their immunocompromised state.⁷⁰ Acute leukemia patients are in need of broad antibiotic coverage, although at the same time, they are more vulnerable to side effects. The ideal treatment should hence be exposure of antimicrobial agents with as narrow antimicrobial specter for as short time as possible. Faster microbiology service has made it possible to faster escalation or de-escalation of the treatment, depending on the chosen treatment strategy.

Norwegian antibiotic-recommendations for treatment of neutropenic fever are penicillin and

aminoglycoside contrary to international recommendations.⁷²⁻⁷⁵ International studies show that aminoglycoside treatment increases the risk of nephrotoxicity compared to beta-lactam treatment. However, studies from countries with a low prevalence of MRDOs like Norway, indicate safety with penicillin and aminoglycoside empiric treatment, given early reconsideration and escalation when necessary.^{72,74} However, significant numbers of patients treated with this regime need treatment alterations, although overall mortality is not increased compared to other studies of FN.⁷²

Invasive Fungal Infections. Invasive fungal infection (IFI) represent an important cause of treatment failure in adults with acute leukemia, and the cumulative probability of developing IFI after a diagnosis of acute leukemia has been estimated to 11.1% at 100 days.¹¹⁸ IFI is a major cause of morbidity and mortality in patients with acute leukemia, and patients treated for hematologic malignancies, and develop a complicating IFI, have an estimated cause specific mortality due to IFI of 35-38 %.^{119,120} AML constitutes the hematologic malignancy with the highest risk of associated IFI. In a report from 2006, Chamilos and coworkers found IFI in 314 of 1017 (31%) autopsies of patients diagnosed with hematologic malignancies, of which only 25% had been diagnosed with IFI while the patients were alive.¹²¹

Data from previous studies have demonstrated; (i) the incidence of IFIs in patients with hematologic malignancies has increased, (ii) over half of IFIs emerge during the remission induction chemotherapy,¹²² (iii) higher age, use of corticosteroid, ANC <0.1 X 10⁹/L at the time of IFI diagnosis, lack of recovery from aplasia, multiple pulmonary localizations of infection and presence of indwelling catheters all negatively influence outcome of IFI.^{123,124}

The most frequently isolated yeast and mold spp. in patients with acute leukemias are presented in **Table 5**. The incidence of the most common fungal infections in patients with acute leukemia has changed in the last decade,¹²⁵ and the incidence of yeast and mold infections show epidemiological variations between regions, depending on the patient population, risk factors and use of antifungal therapy. In certain geographical regions, an association between the incidence of IFI, prevalent diseases, and host factors exists. The occurrence of cryptococcal and *Pneumocystis jirovecii* (*P. jirovecii*) infections are reported in regions with a high prevalence of human immunodeficiency virus (HIV),^{126,127} and diabetes is a risk factor for invasive mold infections.¹²⁸ In mold infections, environmental factors predispose patients for invasive infections, with hospital outbreaks linked to the use of contaminated instruments and devices, Blastomycosis is associated with occupational

Table 5. Major invasive fungal infections in patients with acute leukemia. The table presents the most important fungus, divided in molds, yeasts and mucormycosis, and their main subclasses causing infection in acute leukemia patients.

Molds	Aspergillus spp.	<i>A. fumigatus</i> <i>A. flavus</i>
	Fusarium spp.	<i>F. solani</i> <i>F. oxysporum</i> <i>F. verticillioides</i> <i>F. proliferatum</i>
Yeasts	Candida spp.	<i>C. albicans</i> <i>C. glabrata</i> <i>C. krusei</i> <i>C. tropicalis</i> <i>C. parapsilosis</i>
	Cryptococcus spp.	<i>C. neoformans</i> <i>C. gattii</i> <i>C. albidus</i> <i>C. uniguttulatus</i>
	Tricosporon spp.	<i>T. asahii</i> <i>T. mucoides</i> <i>T. asteroides</i>
	Pneumocystis spp.	<i>P. jirovecii</i>
Mucor mycosis	Rhizopus spp Mucor spp Rhizomucor spp Lichtheimia	<i>R. arrhizus</i> <i>M. circinelloides</i> Rhizomucor spp <i>L. corymbifera</i>

exposure (e.g., forest rangers) and recreational activities (e.g., camping and fishing).^{128,129}

Candida albicans (*C. albicans*) was most frequently isolated in blood cultures in the '80s and '90s. Since the introduction of fluconazole prophylaxis in hematology units, there has been a gradual shift from *C. albicans* to non-*C. albicans* strains.¹³⁰ *Candida* spp. that are fluconazole-resistant (*C. krusei*) or susceptible-dose-dependent (*C. glabrata*) currently account for >80% candidiasis episodes in some hematology units.^{131,132}

A large concurrent surveillance study, Surveillance and Control of Pathogens of Epidemiological Importance (SCOPE), was used to examine the secular trends in the epidemiology and microbiology of nosocomial BSIs. They found *Candida* spp. to be the fourth most common isolated pathogen causing BSIs, and *C. albicans* was the overall most frequently isolated pathogen.¹³³ Invasive aspergillosis in patients with hematologic malignancies and in patients undergoing allo-HSCT is still associated with high morbidity and mortality.^{122,134} There have also been an increase in non-*Aspergillus fumigatus* (*A. fumigatus*) spp., and other mold infections, i.e. *Fusarium* and Mucormycosis.¹³⁵ The emergence of *C. auris* that show resistance to most known antifungals is still not frequent, although it might present as a significant problem in the future.¹³⁶

In a study from Houston, incidence and risk factors for breakthrough invasive mold infections (IMI) in AML patients receiving remission induction chemotherapy were investigated. 17 % of the patients had a possible IMI and only 3.7 % a proven diagnosis of IMI. The incidence of proven or probable IMI per 1000 prophylaxis-days was not statistically different

between anti-*Aspergillus* azoles and micafungin. Older age and relapsed/refractory AML diagnosis were associated with IMI on multivariable analysis.¹³⁷ Introduction of echinocandins and more recently introduced azoles may have contributed to evolve the epidemiology of candidiasis, as incidences of both *C. parapsilosis* and *C. tropicalis* have increased in some treatment centers.^{124,138}

Treatment of Fungal Infections. Fungal treatment could either be empiric, diagnostic driven or directed.¹³⁹ Empiric therapy is used in centers where diagnostics are unavailable, and include broad covering with antifungal treatment after persisting fever for 5-7 days in neutropenic patients, despite antibiotic treatment. The European Conference on Infections in Leukaemia (ECIL)-guidelines recommend either caspofungin or liposomal amphotericin B for empiric treatment.¹⁴⁰ In diagnostic driven treatment, antifungal therapy is started if early markers of fungal infections are presented. Markers for fungal infection used in clinical practice include positive galactomannan (GM)-test; positive beta-D-glucan (BDG)-test, PCR-screening and radiological examinations. Directed therapy is given patients with proven fungal disease.

For invasive candidiasis, echinocandins are first line treatment, although stepdown treatment to i.e. fluconazole, is recommended after susceptibility test results are available.¹⁴¹ Voriconazole, or now recently added isavuconazole, are first line treatment for invasive aspergillosis.¹⁴⁰ Isavuconazole has shown non-inferiority compared to voriconazole, although it has so far shown significantly fewer side effects.¹⁴² Treatment of mucormycosis is challenging and often includes

surgical debridement if possible. Liposomal amphotericin B is first line treatment.^{140,143} *P. jirovecii* is normally treated with trimethoprim-sulfa as long as the treatment is tolerated.¹⁰⁶ Other alternatives for treatment of fungal infections, various fungicides and their antifungal spectrum and important pharmacological properties are presented in **Table 6**,^{140-142,144} and treatment of special problematic fungal infections are presented in **Table 7**.^{106,140-143}

Prophylaxis of Bloodstream Infection and Fever During Neutropenia. Patients with acute leukemias are at risk of developing severe infections related to previously discussed factors (**Figure 1**). In the absence of preventive measures, 48-60% of the patients who became febrile have an established or occult infection.¹⁴⁵

The use of antibiotic prophylaxis has been discussed widely in both Europe and US. According to European and American guidelines, FQs have been recommended as prophylaxis during chemotherapy-induced neutropenia in patients with expected neutropenic periods above seven days.⁸⁴ In consideration of increased antibiotic resistance, the role

of FQ prophylaxis has been reevaluated. A meta-analysis based on two randomized clinical trials and 12 observational studies published between 2006 and 2012 concluded with a reduction of cases with BSI, although without effect on overall mortality rate. Some of the studies also found increased numbers of colonization or infections with MDROs.⁸⁴

The increased frequency of *E. coli* resistance with increased FQ use is well documented and results mainly form mutations in topoisomerase genes or changes in the expression of efflux pumps. It may also be transmitted by plasmids which can transfer ESBL at the same time. The use of FQ has also been linked to the proliferation of several other MDROs such as MRSA, VRE and *C. difficile*.^{146,147} However, patients at high risk of FN should be considered for antimicrobial prophylaxis, including patients with acute leukemias. The risk stratifications should be based on patient characteristics, i.e., advanced age, performance status, nutritional status, prior FN, comorbidity, and their underlying leukemia.¹⁴⁸

In contrast, most patients should not be considered for antifungal prophylaxis, except those that are at risk for profound protracted neutropenia, i.e.

Table 6. Main antifungal treatment options. The table demonstrates the main treatment classes of antifungal therapy; azoles, echinocandins and amphotericin. The most important drugs in each class, their main antifungal specter and main advantages and disadvantages are presented from left to right.

	Drugs	Antifungal specter	Advantages	Disadvantages	References
Azoles	Fluconazole	<i>C.albicans</i> , <i>C.tropicalis</i> , <i>C.parapsilosis</i> , <i>C.glabrata</i> (30-40% resistant) <i>C. neoformans</i>	Good oral bioavailability Good CNS penetration	Substantial drug interactions Substantial <i>C. glabrata</i> resistance Fungustatic, not fungicide	[141]
	Voriconazole	<i>Aspergillus</i> spp., <i>Candida</i> spp., <i>Cryptococcus</i> spp., <i>Fusarium</i> spp.	Used for treatment of <i>Aspergillus</i>	15-50% cross resistance to fluconazole Substantial drug interactions Therapeutic drug monitoring recommended in severe disease	[140]
	Posakonazole	<i>Aspergillus</i> spp., <i>Candida</i> spp.,	Used for prophylaxis for <i>Aspergillus</i>	Substantial drug interactions	[144]
	Isavuconazole	<i>Aspergillus</i> spp., <i>Candida</i> spp., <i>Cryptococcus</i> spp,	Better tolerated than Voriconazol	Substantial drug interactions New medicament	[142]
Echinocandins	Caspofungin	Fungicide: <i>Candida</i> spp. Fungostatic: <i>Aspergillus</i> spp.	Alternative for treatment of <i>aspergillus</i> No dose reduction for renal failure Few drug interactions	Low CNS and bone penetration No urine secretion	[141]
	Mikafungin	Fungocide: <i>Candida</i> spp. Fungostatic: <i>Aspergillus</i> spp.	No dose reduction for renal failure Few drug interactions	Low CNS, eye and bone penetration No urine secretion	[141]
	Anidulafungin	Fungocide: <i>Candida</i> spp. Fungostatic: <i>Aspergillus</i> spp.	No dose reduction for renal failure Less drug interactions	Low CNS and bone penetration No urine secretion Not evaluated for invasive <i>Aspergillus</i>	[141]
Amphotericin B	<i>Candida</i> spp. <i>Aspergillus</i> spp. <i>C. neoformans</i>	Lipid formulation most widely use due to less side effects	Nephrotoxicity, Electrolyte imbalance Anemia	[140]	

Table 7. Treatment options for special problematic fungus. The table shows treatment recommendation for fungus associated with special treatment challenges in patients with acute leukemias. The table is based on European (ECIL) and American (IDSA) recommendations, and references to relevant studies are given in the table. First line treatments are listed first, while second line alternatives are given in parentheses.

Problematic microbes	Recommended antifungal treatment options	References	
Invasive fungal infections	<i>P. jiroveci</i>	Trimetoprim-sulfã (Primaquine + clindamycin, pentamidine)	[106] ^I
	<i>Candida</i> spp.	Ecinocandins (Fluconazole)	[140, 141] ^{L, HSCT}
	<i>Aspergillus</i> spp.	Voriconazole, isavuconazole (Liposomal amphotericin B, caspofungin)	[140] ^{L, HSCT}
	Mucormycosis	Liposomal Amphotericin B (Posakonazole, combination)	[140, 142, 143] ^{L, HSCT}

Indications of febrile neutropenia publications' main weighting/patient cohort are demonstrated: H; Hematological cohorts, L; Leukemia cohorts, HSCT; Hematological stem cell transplantation, I; infections, not neutropenia in general.

relapsed/refractory AML patients or patients undergoing allo-HSCT. These latter patient groups should receive prophylaxis with an oral azole or parenteral echinocandin.^{148,149}

Other Causes of Persistent Fever and Their Management. Occasionally fever may be the only sign of an ongoing infection or non-infectious process in patients with chemotherapy-induced neutropenia; other decisive signs and symptoms of inflammation (erythema, swelling, pain, infiltrates) may be absent. The febrile response is non-specific, and concomitant use of antipyretic drugs (corticosteroids, paracetamol) may suppress fever. As FN is a medical emergency, it is crucial to accurately substantiate the differential diagnosis, as they require different treatment strategies.

Fever in acute leukemia patients can also be attributed to by one of the following reasons; (i) drug fever, (ii) tumor fever (iii) thrombosis, or (iv) rheumatologic disorders. Drug fever is associated with eosinophilia, acute interstitial nephritis, drug-induced hepatitis and disappears rapidly after discontinuation of the particular drug.¹⁵⁰ Tumor fever is one of the most common causes of non-infectious pyrexia in febrile patients with malignancy, and may also occur in leukemia.¹⁵¹ Thrombosis is always important to be aware of, as malignancy is a main risk factor for the development of thrombosis.¹⁵² Rheumatologic disorders are also associated with the clinical manifestations of a number of solid and hematological diseases and represent an important clue during the early diagnosis and treatment of the cancer diseases.¹⁵³

Conclusions. Acute leukemias are a group of malignant blood disorders characterized by a serious clinical course, and the only treatment with curative potential is intensive chemotherapy, possibly combined with allo-HSCT. Infections are important complications to both the diseases themselves and their therapy. Thoroughly diagnostic workup, including microbiological sampling, is the fundament of further handling and treatment. Improvements in both treatment and prophylaxis against both bacterial and fungal infections have helped to improve the treatment results for acute leukemia patients. On the other hand, resistance development to an increasing proportion of the antimicrobial agents we have available is of considerable concern, and this, in turn, can lead to increased morbidity and mortality among leukemia patients from infectious complications. Therefore, physicians, who are treating this specific patient group, must be carefully aware of this increasing problem and make thorough considerations when choosing antimicrobial therapy. In order to make leukemia treatment less toxic, and thereby reduce the risk of serious infections, new searches for new and improved antimicrobial agents are important to further improve treatment outcomes among patients with acute leukemia.

The noteworthy, infectious complication and early mortality seem to be declining with time,¹⁹ since the diagnostic precision, prophylaxis and treatment have increased over the past decades. However, this is currently challenged by the increased risk of resistance development.

References:

- Döhner H, Weisdorf DJ, Bloomfield CD: Acute Myeloid Leukemia. *N Engl J Med* 2015, 373(12):1136-1152. <https://doi.org/10.1056/NEJMra1406184> PMID:26376137
- Terwilliger T, Abdul-Hay M: Acute lymphoblastic leukemia: a comprehensive review and 2017 update. *Blood Cancer J* 2017, 7(6):e577. <https://doi.org/10.1038/bcj.2017.53> PMID:28665419 PMCid:PMC5520400
- Khan M, Siddiqi R, Naqvi K: An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL). *Ann Hematol* 2018, 97(6):945-953. <https://doi.org/10.1007/s00277-018-3297-6> PMID:29546454
- Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med* 1966, 64(2):328-340. <https://doi.org/10.7326/0003-4819-64-2-328> PMID:5216294
- Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. *J Immunol* 2001, 166(1):678-689. <https://doi.org/10.4049/jimmunol.166.1.678> PMID:11123353

6. Ashman LK, Drew PA, Toogood IR, Juttner CA: Immunological competence of patients in remission from acute leukaemia: apparently normal T cell function but defective pokeweed mitogen-driven immunoglobulin synthesis. *Immunol Cell Biol* 1987, 65 (Pt 2):201-210. <https://doi.org/10.1038/icb.1987.22> PMID:2956185
7. Biswal S, Godnaik C: Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards. *Ecancermedscience* 2013, 7:310.
8. Czyzewski K, Galazka P, Fraczkiewicz J, Salamonowicz M, Szymdki-Baran A, Zajac-Spychala O, Gryniewicz-Kwiatkowska O, Zalas-Wiecek P, Chelmecka-Wiktorczyk L, Irga-Jaworska N et al: Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: Impact of national programme of antifungal prophylaxis. *Mycoses* 2019, 62(11):990-998. <https://doi.org/10.1111/myc.12990> PMID:31429997
9. Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC: Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. *Brit J Haematol* 2010, 149(2):263-272. <https://doi.org/10.1111/j.1365-2141.2009.08072.x> PMID:20096013
10. Styczynski J, Czyzewski K, Wysocki M, Gryniewicz-Kwiatkowska O, Kolodziejczyk-Gietka A, Salamonowicz M, Hutnik L, Zajac-Spychala O, Zaucha-Prazmo A, Chelmecka-Wiktorczyk L et al: Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. *Clin Microbiol Infect* 2016, 22(2):179 e171-179 e110. <https://doi.org/10.1016/j.cmi.2015.10.017> PMID:26493843
11. Ossenkoppele G, Lowenberg B: How I treat the older patient with acute myeloid leukemia. *Blood* 2015, 125(5):767-774. <https://doi.org/10.1182/blood-2014-08-551499> PMID:25515963
12. Muller L, Di Benedetto S, Pawelec G: The Immune System and Its Dysregulation with Aging. *Subcell Biochem* 2019, 91:21-43. https://doi.org/10.1007/978-981-13-3681-2_2 PMID:30888648
13. Fanci R, Leoni F, Longo G: Nosocomial infections in acute leukemia: comparison between younger and elderly patients. *New Microbiol* 2008, 31(1):89-96.
14. Halpern AB, Culakova E, Walter RB, Lyman GH: Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. *JAMA Oncol* 2017, 3(3):374-381. <https://doi.org/10.1001/jamaoncol.2016.4858> PMID:27832254 PMID:PMC5344736
15. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D: Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. *Hematology* 2012, 17(2):53-58. <https://doi.org/10.1179/102453312X13221316477651> PMID:22664041
16. Tvedt TH, Reikvam H, Bruserud O: Nutrition in Allogeneic Stem Cell Transplantation--Clinical Guidelines and Immunobiological Aspects. *Curr Pharm Biotechnol* 2016, 17(1):92-104. <https://doi.org/10.2174/138920101701151027163600> PMID:26420050
17. Baumgartner A, Zueger N, Bargetzi A, Medinger M, Passweg JR, Stanga Z, Mueller B, Bargetzi M, Schuetz P: Association of Nutritional Parameters with Clinical Outcomes in Patients with Acute Myeloid Leukemia Undergoing Haematopoietic Stem Cell Transplantation. *Ann Nutr Metab* 2016, 69(2):89-98. <https://doi.org/10.1159/000449451> PMID:27639391
18. Caniza MA, Odio C, Mukkada S, Gonzalez M, Ceppi F, Chaisavaneeyakorn S, Apiwattanakul N, Howard SC, Conter V, Bonilla M: Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries. *Expert Rev Hematol* 2015, 8(5):627-645. <https://doi.org/10.1586/17474086.2015.1071186> PMID:26211675
19. Ho G, Jonas BA, Li Q, Brunson A, Wun T, Keegan THM: Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. *Brit J Haematol* 2017, 177(5):791-799. <https://doi.org/10.1111/bjh.14631> PMID:28419422 PMID:PMC5444943
20. Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM: Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. *Cancer* 2018, 124(9):1938-1945. <https://doi.org/10.1002/cncr.31296> PMID:29451695 PMID:PMC6911353
21. Alvarez EM, Malogolowkin M, Li Q, Brunson A, Pollock BH, Muffly L, Wun T, Keegan THM: Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California. *J Oncol Pract* 2019, 15(4):e316-e327. <https://doi.org/10.1200/JOP.18.00264> PMID:30849003
22. Gill S, Carney D, Ritchie D, Wolf M, Westerman D, Prince HM, Januszewicz H, Seymour JF: The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. *Ann Oncol* 2010, 21(2):331-334. <https://doi.org/10.1093/annonc/mdp297> PMID:19625344
23. Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, Shpilberg O, Douer D, Tallman MS, Raanani P: High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same? *Hematol Oncol* 2016, 34(1):28-35. <https://doi.org/10.1002/hon.2191> PMID:25689584
24. Zajac-Spychala O, Skalska-Sadowska J, Wachowiak J, Szymdki-Baran A, Hutnik L, Matysiak M, Pierlejewski F, Mlynarski W, Czyzewski K, Dziedzic M et al: Infections in children with acute myeloid leukemia: increased mortality in relapsed/refractory patients. *Leuk Lymphoma* 2019:1-8.
25. France MM, Turner JR: The mucosal barrier at a glance. *J Cell Sci* 2017, 130(2):307-314. <https://doi.org/10.1242/jcs.193482> PMID:28062847 PMID:PMC5278669
26. van der Velden WJ, Herbers AH, Netea MG, Blijlevens NM: Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. *Brit J Haematol* 2014, 167(4):441-452. <https://doi.org/10.1111/bjh.13113> PMID:25196917
27. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M: Bacteraemia in febrile neutropenic cancer patients. *Int J Antimicrob Agents* 2007, 30 Suppl 1:S51-59. <https://doi.org/10.1016/j.ijantimicag.2007.06.012> PMID:17689933
28. Kim S, Covington A, Pamer EG: The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. *Immunol Rev* 2017, 279(1):90-105. <https://doi.org/10.1111/imr.12563> PMID:28856737 PMID:PMC6026851
29. Galloway-Pena JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantaji SS, Pemmaraju N et al: The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. *Cancer* 2016, 122(14):2186-2196. <https://doi.org/10.1002/cncr.30039> PMID:27142181 PMID:PMC5574182
30. Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L, No D, Gobourne A, Viale A, Dahi PB et al: The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. *Blood* 2014, 124(7):1174-1182. <https://doi.org/10.1182/blood-2014-02-554725> PMID:24939656 PMID:PMC4133489
31. Luo R, Greenberg A, Stone CD: Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis. *Infect Control Hosp Epidemiol* 2015, 36(7):794-801. <https://doi.org/10.1017/ice.2015.54> PMID:25801085
32. Garcia-Vidal C, Cardozo-Espinola C, Puerta-Alcalde P, Marco F, Tellez A, Agüero D, Romero-Santana F, Diaz-Beya M, Gine E, Morata L et al: Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. *PloS one* 2018, 13(6):e0199531. <https://doi.org/10.1371/journal.pone.0199531> PMID:29953464 PMID:PMC6023133

33. Scheich S, Lindner S, Koenig R, Reinheimer C, Wichelhaus TA, Hogardt M, Besier S, Kempf VAJ, Kessel J, Martin H et al: Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. *Cancer* 2018, 124(2):286-296. <https://doi.org/10.1002/cncr.31045> PMID:28960264
34. Scheich S, Koenig R, Wilke AC, Lindner S, Reinheimer C, Wichelhaus TA, Hogardt M, Kempf VAJ, Kessel J, Weber S et al: *Stenotrophomonas maltophilia* colonization during allogeneic hematopoietic stem cell transplantation is associated with impaired survival. *PLoS one* 2018, 13(7):e0201169. <https://doi.org/10.1371/journal.pone.0201169> PMID:30024969 PMCID:PMC6053200
35. Cattaneo C, Antoniazzi F, Tumbarello M, Skert C, Borlenghi E, Schieppati F, Cerqui E, Pagani C, Petulla M, Re A et al: Relapsing bloodstream infections during treatment of acute leukemia. *Ann Hematol* 2014, 93(5):785-790. <https://doi.org/10.1007/s00277-013-1965-0> PMID:24288110
36. Tanir Basaranoglu S, Ozsurekci Y, Aykac K, Karadag Oncel E, Bicakcigil A, Sancak B, Cengiz AB, Kara A, Ceyhan M: A comparison of blood stream infections with extended spectrum beta-lactamase-producing and non-producing *Klebsiella pneumoniae* in pediatric patients. *Ital J Pediatr* 2017, 43(1):79. <https://doi.org/10.1186/s13052-017-0398-0> PMID:28899399 PMCID:PMC5596860
37. Arnan M, Gudiol C, Calatayud L, Linares J, Dominguez MA, Batlle M, Ribera JM, Carratala J, Gudiol F: Risk factors for, and clinical relevance of, bacteremia in patients with hematological malignancies. *Eur J Clin Microbiol Infect Dis* 2011, 30(3):355-360. <https://doi.org/10.1007/s10096-010-1093-x> PMID:21052757
38. Cornejo-Juarez P, Suarez-Cuenca JA, Volkow-Fernandez P, Silva-Sanchez J, Barrios-Camacho H, Najera-Leon E, Velazquez-Acosta C, Vilar-Compte D: Fecal ESBL *Escherichia coli* carriage as a risk factor for bacteremia in patients with hematological malignancies. *Support Care Cancer* 2016, 24(1):253-259. <https://doi.org/10.1007/s00520-015-2772-z> PMID:26014616
39. Karthaus M, Doellmann T, Klimasch T, Krauter J, Heil G, Ganser A: Central venous catheter infections in patients with acute leukemia. *Chemotherapy* 2002, 48(3):154-157. <https://doi.org/10.1159/000064922> PMID:12138333
40. Theodoro D, Olsen MA, Warren DK, McMullen KM, Asaro P, Henderson A, Tozier M, Fraser V: Emergency Department Central Line-associated Bloodstream Infections (CLABSI) Incidence in the Era of Prevention Practices. *Acad Emerg Med* 2015, 22(9):1048-1055. <https://doi.org/10.1111/acem.12744> PMID:26336036 PMCID:PMC4703118
41. Kugler E, Levi A, Goldberg E, Zaig E, Raanani P, Paul M: The association of central venous catheter placement timing with infection rates in patients with acute leukemia. *Leuk Res* 2015, 39(3):311-313. <https://doi.org/10.1016/j.leukres.2014.12.017> PMID:25636357
42. Jaeger K, Zenz S, Juttner B, Ruschulte H, Kuse E, Heine J, Piepenbrock S, Ganser A, Karthaus M: Reduction of catheter-related infections in neutropenic patients: a prospective controlled randomized trial using a chlorhexidine and silver sulfadiazine-impregnated central venous catheter. *Ann Hematol* 2005, 84(4):258-262. <https://doi.org/10.1007/s00277-004-0972-6> PMID:15549302
43. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, Lemiale V, Seguin A, Darmon M, Schlemmer B et al: Survival in neutropenic patients with severe sepsis or septic shock. *Crit Care Med* 2012, 40(1):43-49. <https://doi.org/10.1097/CCM.0b013e31822b50c2> PMID:21926615
44. Gao Y, Liu Y, Ma X, Wei L, Chen W, Song L: The incidence and risk factors of peripherally inserted central catheter-related infection among cancer patients. *Ther Clin Risk Manag* 2015, 11:863-871. <https://doi.org/10.2147/TCRM.S83776> PMID:26045668 PMCID:PMC4447175
45. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Cooper-Smith CM et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016, 315(8):801-810. <https://doi.org/10.1001/jama.2016.0287> PMID:26903338 PMCID:PMC4968574
46. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL: Serial evaluation of the SOFA score to predict outcome in critically ill patients. *Jama* 2001, 286(14):1754-1758. <https://doi.org/10.1001/jama.286.14.1754> PMID:11594901
47. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R et al: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. *Blood* 1996, 87(5):1710-1717. <https://doi.org/10.1182/blood.V87.5.1710.bloodjournal8751710> PMID:8634416
48. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. *Blood* 1995, 85(8):2025-2037. <https://doi.org/10.1182/blood.V85.8.2025.bloodjournal8582025> PMID:7718875
49. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Intensive Care Med* 2003, 29(4):530-538. <https://doi.org/10.1007/s00134-003-1662-x> PMID:12664219
50. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K et al: Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. *J Clin Oncol* 2018, 36(14):1443-1453. <https://doi.org/10.1200/JCO.2017.77.6211> PMID:29461916
51. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J Clin Oncol* 2000, 18(16):3038-3051. <https://doi.org/10.1200/JCO.2000.18.16.3038> PMID:10944139
52. Coyne CJ, Le V, Brennan JJ, Castillo EM, Shatsky RA, Ferran K, Brodine S, Vilke GM: Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department. *Ann Emerg Med* 2017, 69(6):755-764. <https://doi.org/10.1016/j.annemergmed.2016.11.007> PMID:28041827
53. Lee SJ, Kim JH, Han SB, Paik JH, Durey A: Prognostic Factors Predicting Poor Outcome in Cancer Patients with Febrile Neutropenia in the Emergency Department: Usefulness of qSOFA. *J Oncol* 2018, 2018:2183179. <https://doi.org/10.1155/2018/2183179> PMID:30405714 PMCID:PMC6201329
54. Kim M, Ahn S, Kim WY, Sohn CH, Seo DW, Lee YS, Lim KS: Predictive performance of the quick score Sequential Organ Failure Assessment as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia. *Support Care Cancer* 2017, 25(5):1557-1562. <https://doi.org/10.1007/s00520-016-3567-6> PMID:28062972
55. Rolston KV: Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. *Clin Infect Dis* 2005, 40 Suppl 4:S246-252. <https://doi.org/10.1086/427331> PMID:15768330
56. Collin BA, Leather HL, Wingard JR, Ramphal R: Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. *Clin Infect Dis* 2001, 33(7):947-953. <https://doi.org/10.1086/322604> PMID:11528564
57. Pittet D, Tarara D, Wenzel RP: Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. *JAMA* 1994, 271(20):1598-1601. <https://doi.org/10.1001/jama.271.20.1598> PMID:8182812

58. Klastersky J: Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness. *Curr Opin Oncol* 1998, 10(4):284-290.
<https://doi.org/10.1097/00001622-199807000-00002>
PMid:9702394
59. Viscoli C: The evolution of the empirical management of fever and neutropenia in cancer patients. *J Antimicrob Chemother* 1998, 41 Suppl D:65-80.
https://doi.org/10.1093/jac/41.suppl_4.65
PMid:9688453
60. Armstrong D: History of opportunistic infection in the immunocompromised host. *Clin Infect Dis* 1993, 17 Suppl 2:S318-321.
https://doi.org/10.1093/clinids/17.Supplement_2.S318
PMid:8274594
61. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, 3rd: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. *N Engl J Med* 1994, 331(14):896-903.
<https://doi.org/10.1056/NEJM199410063311402>
PMid:8078551
62. Lakshmaiah KC, Malabagi AS, Govindbabu, Shetty R, Sinha M, Jayashree RS: Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients. *J Lab Physicians* 2015, 7(2):116-120.
<https://doi.org/10.4103/0974-2727.163126>
PMid:26417163 PMCid:PMC4559624
63. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad, II, Rolston KV, Young JA, Wingard JR et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. *Clin Infect Dis* 2011, 52(4):e56-93.
<https://doi.org/10.1093/cid/cir073>
PMid:21258094
64. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R et al: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med* 2013, 41(2):580-637.
<https://doi.org/10.1007/s00134-012-2769-8>
PMid:23361625
65. Menzo SL, la Martire G, Ceccarelli G, Venditti M: New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies. *Mediterr J Hematol Infect Dis* 2015, 7(1):e2015044.
<https://doi.org/10.4084/mjhid.2015.044>
PMid:26185609 PMCid:PMC4500473
66. Ricciardi W, Giubbini G, Laurenti P: Surveillance and Control of Antibiotic Resistance in the Mediterranean Region. *Mediterr J Hematol Infect Dis* 2016, 8(1):e2016036.
<https://doi.org/10.4084/mjhid.2016.036>
PMid:27413528 PMCid:PMC4928537
67. Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, Chiu A, Raybardhan S, Science M, Fernando E et al: Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. *J Antimicrob Chemother* 2015, 70(5):1539-1546.
<https://doi.org/10.1093/jac/dku560>
PMid:25614044
68. Hassoun A, Linden PK, Friedman B: Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment. *Crit Care* 2017, 21(1):211.
<https://doi.org/10.1186/s13054-017-1801-3>
PMid:28807042 PMCid:PMC5557425
69. Mikulska M, Del Bono V, Viscoli C: Bacterial infections in hematopoietic stem cell transplantation recipients. *Curr Opin Hematol* 2014, 21(6):451-458.
<https://doi.org/10.1097/MOH.0000000000000088>
PMid:25295742
70. Satlin MJ, Walsh TJ: Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients. *Transpl Infect Dis* 2017, 19(6).
<https://doi.org/10.1111/tid.12762>
PMid:28815897 PMCid:PMC5745272
71. Bartlett JG: Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. *Annals of internal medicine* 2006, 145(10):758-764.
<https://doi.org/10.7326/0003-4819-145-10-200611210-00008>
PMid:17116920
72. Torfoss D: Carbapenems and febrile neutropenia - author's reply. *Clin Microbiol Infect* 2017, 23(3):214.
<https://doi.org/10.1016/j.cmi.2016.12.019>
PMid:28025133
73. Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Floisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK et al: Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial. *Clin Microbiol Infect* 2017, 23(3):179-187.
<https://doi.org/10.1016/j.cmi.2016.10.019>
PMid:27793737
74. Torfoss D, Hoiby EA, Holte H, Kvaloy S: The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review. *Acta Oncol* 2012, 51(4):433-440.
<https://doi.org/10.3109/0284186X.2011.633931>
PMid:22175253
75. Torfoss D, Hoiby EA, Tangen JM, Holte H, Bo K, Meyer P, Grotttum K, Weyde K, Lauritzen GF, Sandstad B et al: Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. *J Antimicrob Chemother* 2007, 59(4):711-717.
<https://doi.org/10.1093/jac/dkm003>
PMid:17327294
76. Perez F, Adachi J, Bonomo RA: Antibiotic-resistant gram-negative bacterial infections in patients with cancer. *Clin Infect Dis* 2014, 59 Suppl 5:S335-339.
<https://doi.org/10.1093/cid/ciu612>
PMid:25352627 PMCid:PMC4303050
77. Gudiol C, Royo-Cebrecos C, Tebe C, Abdala E, Akova M, Alvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT et al: Clinical efficacy of beta-lactam/beta-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). *BMJ Open* 2017, 7(1):e013268.
<https://doi.org/10.1136/bmjopen-2016-013268>
PMid:28115333 PMCid:PMC5278288
78. Bassetti M, Giacobbe DR, Giamarellou H, Viscoli C, Daikos GL, Dimopoulos G, De Rosa FG, Giamarellos-Bourboulis EJ, Rossolini GM, Righi E et al: Management of KPC-producing Klebsiella pneumoniae infections. *Clin Microbiol Infect* 2018, 24(2):133-144.
<https://doi.org/10.1016/j.cmi.2017.08.030>
PMid:28893689
79. Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pano-Pardo JR, Venditti M, Tumbarello M, Daikos G, Canton R et al: Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. *Lancet Infect Dis* 2017, 17(7):726-734.
80. Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O et al: A Multinational, Preregistered Cohort Study of beta-Lactam/beta-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae. *Antimicrob Agents Chemother* 2016, 60(7):4159-4169.
<https://doi.org/10.1128/AAC.00365-16>
PMid:27139473 PMCid:PMC4914653
81. Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O et al: Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). *Haematologica* 2013, 98(12):1836-1847.
<https://doi.org/10.3324/haematol.2013.091330>
PMid:24323984 PMCid:PMC3856958
82. Kengkla K, Kongpakwattana K, Saokaew S, Apisanthanarak A, Chaiyakunapruk N: Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. *J Antimicrob Chemother* 2018, 73(1):22-32.
<https://doi.org/10.1093/jac/dkx368>
PMid:29069421
83. Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L, Pabst T, Ozcelik T, Klyasova G, Donnini I et al: Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental

- Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. *Clin Infect Dis* 2017, 65(11):1819-1828.
<https://doi.org/10.1093/cid/cix646>
PMid:29020364
84. Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C, European Conference on Infections in L: Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. *J Infect* 2018, 76(1):20-37.
<https://doi.org/10.1016/j.jinf.2017.10.009>
PMid:29079323
85. Karimi F, Ashrafi F, Moghaddas A, Derakhshandeh A: Management of Febrile Neutropenia: A Description of Clinical and Microbiological Findings by Focusing on Risk Factors and Pitfalls. *J Res Pharm Pract* 2018, 7(3):147-156.
<https://doi.org/10.4103/jrpp.JRPP.18.16>
PMid:30211240 PMCid:PMC6121758
86. Gustinetti G, Mikulska M: Bloodstream infections in neutropenic cancer patients: A practical update. *Virulence* 2016, 7(3):280-297.
<https://doi.org/10.1080/21505594.2016.1156821>
PMid:27002635 PMCid:PMC4871679
87. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. *Clin Infect Dis* 2003, 36(9):1103-1110.
<https://doi.org/10.1086/374339>
PMid:12715303
88. van Duin D, Paterson DL: Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned. *Infect Dis Clin North Am* 2016, 30(2):377-390.
<https://doi.org/10.1016/j.idc.2016.02.004>
PMid:27208764 PMCid:PMC5314345
89. Laws M, Shaaban A, Rahman KM: Antibiotic resistance breakers: current approaches and future directions. *FEMS Microbiol Rev* 2019, 43(5):490-516.
<https://doi.org/10.1093/femsre/fuz014>
PMid:31150547 PMCid:PMC6736374
90. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O et al: European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. *Haematologica* 2013, 98(12):1826-1835.
<https://doi.org/10.3324/haematol.2013.091025>
PMid:24323983 PMCid:PMC3856957
91. Balletto E, Mikulska M: Bacterial Infections in Hematopoietic Stem Cell Transplant Recipients. *Mediterr J Hematol Infect Dis* 2015, 7(1):e2015045.
<https://doi.org/10.4084/mjh.2015.045>
PMid:26185610 PMCid:PMC4500472
92. Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, Akova M, Fourth European Conference on Infections in Leukemia Group ajvoEEIELN, Esgich/Esamid: Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. *J Infect* 2014, 68(4):321-331.
<https://doi.org/10.1016/j.jinf.2013.12.006>
PMid:24370562
93. Lambert PA: Mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*. *J R Soc Med* 2002, 95 Suppl 41:22-26.
94. Horasan ES, Ersoz G, Tombak A, Tiftik N, Kaya A: Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients. *Med Sci Monit* 2011, 17(5):CR304-309.
<https://doi.org/10.12659/MSM.881773>
PMid:21525814 PMCid:PMC3539578
95. Kolonen A, Sinisalo M, Huttunen R, Syrjanen J, Aittoniemi J, Huhtala H, Sankelo M, Rintala H, Raty R, Jantunen E et al: Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study. *Infect Dis (Lond)* 2017, 49(11-12):799-808.
<https://doi.org/10.1080/23744235.2017.1347814>
PMid:28683646
96. Macesic N, Morrissey CO, Cheng AC, Spencer A, Peleg AY: Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period. *Transpl Infect Dis* 2014, 16(6):887-896.
<https://doi.org/10.1111/tid.12298>
PMid:25298044
97. Vydra J, Shanley RM, George I, Ustun C, Smith AR, Weisdorf DJ, Young JA: Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis* 2012, 55(6):764-770.
<https://doi.org/10.1093/cid/cis550>
PMid:22693346 PMCid:PMC3657510
98. Tavazde M, Rybicki L, Mossad S, Avery R, Yurch M, Pohlman B, Duong H, Dean R, Hill B, Andresen S et al: Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant* 2014, 49(10):1310-1316.
<https://doi.org/10.1038/bmt.2014.150>
PMid:25111516
99. Jaffe D, Jakubowski A, Sepkowitz K, Sebt R, Kiehn TE, Pamer E, Papanicolaou GA: Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. *Clin Infect Dis* 2004, 39(11):1625-1632.
<https://doi.org/10.1086/425612>
PMid:15578362
100. Shenep JL: Viridans-group streptococcal infections in immunocompromised hosts. *Int J Antimicrob Agents* 2000, 14(2):129-135.
[https://doi.org/10.1016/S0924-8579\(99\)00172-7](https://doi.org/10.1016/S0924-8579(99)00172-7)
101. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM et al: A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. *N Engl J Med* 1999, 341(5):305-311.
<https://doi.org/10.1056/NEJM199907293410501>
PMid:10423464
102. Lodise TP, Jr., Lomaestro B, Drusano GL: Piperacillin-tazobactam for *Pseudomonas aeruginosa* infection: clinical implications of an extended-infusion dosing strategy. *Clin Infect Dis* 2007, 44(3):357-363.
<https://doi.org/10.1086/510590>
PMid:17205441
103. Krause KM, Serio AW, Kane TR, Connolly LE: Aminoglycosides: An Overview. *Cold Spring Harb Perspect Med* 2016, 6(6).
<https://doi.org/10.1101/cshperspect.a027029>
PMid:27252397 PMCid:PMC4888811
104. Kassamali Z, Danziger L: To B or not to B, that is the question: is it time to replace colistin with polymyxin B? *Pharmacotherapy* 2015, 35(1):17-21.
<https://doi.org/10.1002/phar.1510>
PMid:25346395
105. Parker S, Lipman J, Kourenti D, Dimopoulos G, Roberts JA: What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. *Int J Antimicrob Agents* 2013, 42(4):289-293.
<https://doi.org/10.1016/j.ijantimicag.2013.05.018>
PMid:23880170
106. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P: ECIL guidelines for treatment of *Pneumocystis jirovecii* pneumonia in non-HIV-infected haematology patients. *J Antimicrob Chemother* 2016, 71(9):2405-2413.
<https://doi.org/10.1093/jac/dkw158>
PMid:27550993
107. Gums JG, Boatwright DW, Camblin M, Halstead DC, Jones ME, Sanderson R: Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. *Ann Pharmacother* 2008, 42(1):71-79.
<https://doi.org/10.1345/aph.1H620>
PMid:18094350
108. Bijie H, Kulpradist S, Manalaysay M, Soebandrio A: In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. *J Chemother* 2005, 17(1):3-24.
109. Wang FD, Liu CY, Hsu HC, Gau JP, Chau WK, Haung ML, Ho CH: A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. *Chemotherapy* 1999, 45(5):370-379.
<https://doi.org/10.1159/000007228>
PMid:10473925
110. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, Lemeshow S, Osborn T, Terry KM, Levy MM: Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. *N Engl J Med* 2017, 376(23):2235-2244.
<https://doi.org/10.1056/NEJMoa1703058>
PMid:28528569 PMCid:PMC5538258

111. Wendelbo O, Hervig T, Haugen O, Seghatchian J, Reikvam H: Microcirculation and red cell transfusion in patients with sepsis. *Transfus Apher Sci* 2017, 56(6):900-905. <https://doi.org/10.1016/j.transci.2017.11.020> PMID:29158076
112. Klastersky J: Empirical antibiotic therapy in neutropenic cancer patients. *Eur J Cancer* 1993, 29A Suppl 1:S6-10. [https://doi.org/10.1016/S0959-8049\(05\)80253-9](https://doi.org/10.1016/S0959-8049(05)80253-9)
113. Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrmbecher T: Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. *Lancet Oncol* 2014, 15(8):e327-340. [https://doi.org/10.1016/S1470-2045\(14\)70017-8](https://doi.org/10.1016/S1470-2045(14)70017-8)
114. Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Alvarez R, Maestrodella Calle G, Cano A, Cervera C, Clemente WT, Martin-Davila P et al: Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. *Antimicrob Agents Chemother* 2017, 61(8). <https://doi.org/10.1128/AAC.00164-17> PMID:28584145 PMCid:PMC527609
115. Adegoke AA, Stenstrom TA, Okoh AI: *Stenotrophomonas maltophilia* as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy. *Front Microbiol* 2017, 8:2276. <https://doi.org/10.3389/fmicb.2017.02276> PMID:29250041 PMCid:PMC5714879
116. Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME: beta-Lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for *Pseudomonas aeruginosa* infections: a meta-analysis. *Int J Antimicrob Agents* 2013, 41(4):301-310. <https://doi.org/10.1016/j.ijantimicag.2012.12.006> PMID:23410791
117. Davies J, Davies D: Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev* 2010, 74(3):417-433. <https://doi.org/10.1128/MMBR.00016-10> PMID:20805405 PMCid:PMC2937522
118. Hammond SP, Marty FM, Bryar JM, DeAngelo DJ, Baden LR: Invasive fungal disease in patients treated for newly diagnosed acute leukemia. *Am J Hematol* 2010, 85(9):695-699. <https://doi.org/10.1002/ajh.21776> PMID:20652970
119. Auberger J, Lass-Flörl C, Ulmer H, Nogler-Semenitz E, Clausen J, Gunsilius E, Einsele H, Gastl G, Nachbaur D: Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. *Int J Hematol* 2008, 88(5):508-515. <https://doi.org/10.1007/s12185-008-0184-2> PMID:18982251
120. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikian-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E et al: ESCMID* guideline for the diagnosis and management of *Candida* diseases 2012: adults with hematological malignancies and after hematopoietic stem cell transplantation (HCT). *Clin Microbiol Infect* 2012, 18 Suppl 7:53-67. <https://doi.org/10.1111/1469-0691.12041> PMID:23137137
121. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad, II, Kontoyiannis DP: Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). *Haematologica* 2006, 91(7):986-989.
122. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A et al: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. *Haematologica* 2006, 91(8):1068-1075.
123. Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA: Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. *Haematologica* 2012, 97(3):459-463. <https://doi.org/10.3324/haematol.2011.051995> PMID:22058198 PMCid:PMC3291603
124. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad, II, Kontoyiannis DP: Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. *Cancer* 2009, 115(20):4745-4752. <https://doi.org/10.1002/cncr.24507> PMID:19634156
125. von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely OA, Kurzai O: Invasive Fungal Infection. *Dtsch Arztebl Int* 2019, 116(16):271-278. <https://doi.org/10.3238/arztebl.2019.0271> PMID:31159914 PMCid:PMC6549129
126. Maini R, Henderson KL, Sheridan EA, Lamagni T, Nichols G, Delpech V, Phin N: Increasing *Pneumocystis pneumonia*, England, UK, 2000-2010. *Emerg Infect Dis* 2013, 19(3):386-392. <https://doi.org/10.3201/eid1903.121151> PMID:23622345 PMCid:PMC3647665
127. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR: Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis* 2017, 17(8):873-881. [https://doi.org/10.1016/S1473-3099\(17\)30243-8](https://doi.org/10.1016/S1473-3099(17)30243-8)
128. Prakash H, Chakrabarti A: Global Epidemiology of *Mucormycosis*. *J Fungi (Basel)* 2019, 5(1). <https://doi.org/10.3390/jof5010026> PMID:30901907 PMCid:PMC6462913
129. Seitz AE, Adjemian J, Steiner CA, Prevots DR: Spatial epidemiology of blastomycosis hospitalizations: detecting clusters and identifying environmental risk factors. *Med Mycol* 2015, 53(5):447-454. <https://doi.org/10.1093/mmy/myv014> PMID:25908653
130. Keighley C, Chen SC, Marriott D, Pope A, Chapman B, Kennedy K, Bak N, Underwood N, Wilson HL, McDonald K et al: *Candidaemia* and a risk predictive model for overall mortality: a prospective multicentre study. *BMC Infect Dis* 2019, 19(1):445. <https://doi.org/10.1186/s12879-019-4065-5> PMID:31113382 PMCid:PMC6528341
131. Pagano L, Antinori A, Ammassari A, Mele L, Nosari A, Melillo L, Martino B, Sanguinetti M, Equitani F, Nobile F et al: Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. *Eur J Haematol* 1999, 63(2):77-85. <https://doi.org/10.1111/j.1600-0609.1999.tb01120.x> PMID:10480286
132. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM: Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. *Clin Infect Dis* 2009, 48(12):1695-1703. <https://doi.org/10.1086/599039> PMID:19441981
133. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis* 2004, 39(3):309-317. <https://doi.org/10.1086/421946> PMID:15306996
134. Nicolle MC, Benet T, Thiebaut A, Bienvenu AL, Voirin N, Duclos A, Sobh M, Cannas G, Thomas X, Nicolini FE et al: Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. *Haematologica* 2011, 96(11):1685-1691. <https://doi.org/10.3324/haematol.2011.044636> PMID:21791468 PMCid:PMC3208687
135. Bhatt VR, Viola GM, Ferrajoli A: Invasive fungal infections in acute leukemia. *Ther Adv Hematol* 2011, 2(4):231-247. <https://doi.org/10.1177/2040620711410098> PMID:23556092 PMCid:PMC3573411
136. Lone SA, Ahmad A: *Candida auris*-the growing menace to global health. *Mycoses* 2019, 62(8):620-637. <https://doi.org/10.1111/myc.12904> PMID:30773703
137. Patel HP, Perissinotti AJ, Patel TS, Bixby DL, Marshall VD, Marini BL: Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy. *Open Forum Infect Dis* 2019, 6(5):ofz176. <https://doi.org/10.1093/ofid/ofz176> PMID:31123689 PMCid:PMC6524834
138. Kimura M, Araoka H, Yamamoto H, Asano-Mori Y, Nakamura S, Yamagoe S, Ohno H, Miyazaki Y, Abe M, Yuasa M et al: Clinical and Microbiological Characteristics of Breakthrough Candidemia in

- Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital. *Antimicrob Agents Chemother* 2017, 61(4).
<https://doi.org/10.1128/AAC.01791-16>
 PMID:28115352 PMCID:PMC5365651
139. Mercier T, Maertens J: Clinical considerations in the early treatment of invasive mould infections and disease. *J Antimicrob Chemother* 2017, 72(suppl_1):i29-i38.
<https://doi.org/10.1093/jac/dkx031>
 PMID:28355465
140. Tissot F, Agrawal S, Pagano L, Petrikos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R: ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. *Haematologica* 2017, 102(3):433-444.
<https://doi.org/10.3324/haematol.2016.152900>
 PMID:28011902 PMCID:PMC5394968
141. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ: Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. *Clin Infect Dis* 2012, 54(8):1110-1122.
<https://doi.org/10.1093/cid/cis021>
 PMID:22412055
142. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M et al: Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet* 2016, 387(10020):760-769.
[https://doi.org/10.1016/S0140-6736\(15\)01159-9](https://doi.org/10.1016/S0140-6736(15)01159-9)
143. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikos GL, European Conference on Infections in Leukemia: Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). *Haematologica* 2013, 98(4):492-504.
<https://doi.org/10.3324/haematol.2012.065110>
 PMID:22983580 PMCID:PMC3659979
144. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA et al: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 2008, 46(3):327-360.
<https://doi.org/10.1086/525258>
 PMID:18177225
145. Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer LC, Leibovici L: Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. *Cochrane Database Syst Rev* 2012, 1:CD004386.
<https://doi.org/10.1002/14651858.CD004386.pub3>
 PMCID:PMC4170789
146. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, Mohapatra S, Trenholme GM, Klugman KP, McCormack JG et al: Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in *Klebsiella pneumoniae* isolates causing bacteremia. *Clin Infect Dis* 2000, 30(3):473-478.
<https://doi.org/10.1086/313719>
 PMID:10722430
147. Slavin MA, Lingaratnam S, Mileskin L, Booth DL, Cain MJ, Ritchie DS, Wei A, Thursky KA, Australian Consensus Guidelines Steering C: Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. *Intern Med J* 2011, 41(1b):102-109.
<https://doi.org/10.1111/j.1445-5994.2010.02341.x>
 PMID:21272174
148. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV et al: Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. *J Clin Oncol* 2018, 36(30):3043-3054.
<https://doi.org/10.1200/JCO.18.00374>
 PMID:30179565
149. Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racl Z, Ribaud P, Slavin MA, Cornely OA et al: European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. *J Antimicrob Chemother* 2018, 73(12):3221-3230.
<https://doi.org/10.1093/jac/dky286>
150. Patel RA, Gallagher JC: Drug fever. *Pharmacotherapy* 2010, 30(1):57-69.
<https://doi.org/10.1592/phco.30.1.57>
 PMID:20030474
151. Toussaint E, Bahel-Ball E, Vekemans M, Georgala A, Al-Hakak L, Paesmans M, Aoun M: Causes of fever in cancer patients (prospective study over 477 episodes). *Support Care Cancer* 2006, 14(7):763-769.
<https://doi.org/10.1007/s00520-005-0898-0>
 PMID:16528534
152. Mosevoll KA, Johansen S, Wendelbo O, Nepstad I, Bruserud O, Reikvam H: Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. *Front Med (Lausanne)* 2018, 5:147.
<https://doi.org/10.3389/fmed.2018.00147>
 PMID:29872658 PMCID:PMC5972295
153. Racanelli V, Prete M, Minoia C, Favoino E, Perosa F: Rheumatic disorders as paraneoplastic syndromes. *Autoimmun Rev* 2008, 7(5):352-358.
<https://doi.org/10.1016/j.autrev.2008.02.001>
 PMID:18486921